ClinicalTrials.gg
RecruitingNCT06852859Updated Nov 17, 2026

Patient-reported Pain and Symptom Relief During Three Months After Surgery for Benign Prostatic Hyperplasia

An observational study in Benign Prostatic Hyperplasia, sponsored by Sahlgrenska University Hospital. Recruiting at 3 sites in Sweden. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Sahlgrenska University Hospital · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Updated Nov 17, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
50 Years and older
Sex
Male
01

Study summary

This is a prospective observational study in patients undergoing surgery for benign prostatic hyperplasia (BPH).

The purpose of the study is to investigate in great detail patients' recovery after surgery for BPH regarding pain, hematuria, urine leakage and use of pain-relieving medications for three months postoperatively. Patient-reported outcomes after three different surgical methods will be investigated: transurethral resection, transurethral vaporization and laser transurethral enucleation of the prostate (Green-LEP)

Research questions:

  • How do patients rate their day-to-day pain during the first three months after surgery for BPH? How long does it take to be pain free?
  • How does the patient estimate any day-to-day burning sensation during the first three months after surgery for BPH?
  • How many painkilling tablets of a certain preparation and a certain strength take patients per day in the first three months after surgery for BPH?
  • How long do patients have urinary leakage after surgery for BPH?
  • Are the patients bothered by possible urine leakage and if so for how long after surgery for BPH?
  • How long does one have macroscopic hematuria after surgery for BPH?
  • How quickly are the patients' urinary tract problems affected according to the IPSS per month?
  • Are the results on the above outcome measures different between the three TUR-P methods, TUV-P and Green LEP?
Read the detailed description

Design and selection:

This is a prospective multicenter observational study in which patients undergoing TUR-P, TUV-P and GreenLEP for BPH are included. The subjects will be followed up with a self-assessment form that is completed daily for three months and then sent to the responsible researchers. After this, the research subjects will be followed up with sent out IPSS forms after six months, and then annually for up to five years. These are sent in stamped envelopes.

Participants:

The study will include 500 patients who undergo surgery for BPH at Alingsås hospital, Sjukhusen i Väster and Sahlgrenska University Hospital, as well as possibly an additional urology clinic in the future. The inclusion criteria include men over 50 years of age with diagnosed BPH and LUTS who have an indication for surgery with any of the three methods studied.

Outcome measures:

  1. Pain and burning will be assessed using the NRS (numeric scale) between 0 and 10 where 0 is defined as "no pain/burning" and 10 is defined as "worst imaginable pain/burning". The researchers fill in this day-by-day for three months
  2. Use of pain-relieving medications will be investigated with a table in which the research subjects enter drug names and sum up the number of tablets taken per day.
  3. Urine leakage will be examined by the research subjects checking either "Yes" or "no" on the question of whether they have had urine leakage on a daily basis.
  4. If this urine leakage has bothered the research subjects, it is investigated by ticking either "Yes" or "No" daily as a follow-up question to the previous one.
  5. The duration of hematuria will be examined by the research subjects checking either "Yes" or "No" on the question of whether they have had blood in the urine daily
  6. The change in LUTS measured by IPSS will be used to measure patient-perceived outcomes at baseline, after four, eight and twelve weeks, after six months and then annually for five years.

Data Analysis:

Descriptive statistics will be used to compile the PROMs data. Changes over time will be analyzed using repeated measures (ANOVA). Differences in outcome measures between the three different methods will be analyzed with the Mann-Whitney test for continuous, independent data pairs, and the Chi-Square test for categorical variables.

Ethical considerations:

The study will be conducted in accordance with the Declaration of Helsinki, and all participants will give their informed consent. Ethical approval will be sought from the Ethical Review Authority (EPM)

Significance and clinical relevance:

The results of this study will provide important insights into how patient-reported outcomes after benign prostate surgery can be used to improve surgical outcomes and patient counseling. The results will also be able to be used to compare outcome measures between the three different treatments used for BPH. By highlighting the patient's perspective, care can be developed to better meet the patients' needs and expectations, and by determining a "normal course" regarding these outcome measures, the results can also be used in the future to identify patients who deviate from the expected recovery course.

02

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

03

In context

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

This study's planned enrollment of 500 is above the median of 250 across 177 observational studies indexed under Prostatic Hyperplasia.

Browse Prostatic Hyperplasia studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 67 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients scheduled for surgery for benign prostatic hyperplasia

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing transurethral surgery for benign prostatic hyperplasia
  • Singed to participate

Exclusion criteria

Exclusion Criteria:

  • Non-swedish speaking patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patient treated by transurethral surgical procedure

    Patients treated for BPH with surgery

    Procedure: Transurethral resection of the prostate · Procedure: Transurethral vaporization of the prostate · Procedure: GreenLight laser enucleation of the prostate

Interventions

  • ProcedureTransurethral resection of the prostate

    Thermocoagulation is used in contrast to the other methods

  • ProcedureTransurethral vaporization of the prostate

    Heat is used to vaporize prostate

  • ProcedureGreenLight laser enucleation of the prostate

    laser is used in contrast to the other methods

06

What researchers measure

Primary outcomes

  1. Change in postoperative pain levels

    Day-by-day registration of pain by NRS (numeric response scale) for pain. Anchorpoints: 0 (no pain) to 10 (worst possible pain)

    Time frame: Day-by-day for three months

Secondary outcomes

  1. Use of analgesics postoperatively

    Patients are to report all pain medication used day-by-day

    Time frame: Day-by-day for three months

  2. Duration of postoperative hematuria

    The patients register the incidence of hematuria day-by-day by checking either "yes" or "no"

    Time frame: Day-by-day for three months

  3. Duration of postoperative leakage of urine

    The patients record the incidence of leakage of urine day-by-day by checking either "yes" or "no" box

    Time frame: Day-by-day for three months

  4. Concerns about urine leakage

    If the patients have checked the box "yes" for urine leakage, they are asked to record if they are bothered by this leakage or not by checking either "yes" or "no" box

    Time frame: Day-by-day for three months

  5. Changes in Lower Urinary Tract Symptoms as measured by the IPSS questionnaire

    The patients are asked to complete the IPSS (International Prostatic Symptom Score) once a month. The IPSS is made up of 7 questions related to voiding symptoms. A score of 0 to 7 indicates mild symptoms, 8 to 19 indicates moderate symptoms and 20 to 35 indicates severe symptoms.

    Time frame: Month-by-month for 3 months

07

Study locations

1 of 3 sites recruiting
  • Kungälvs sjukhus, department of urology
    Kungälv, Sweden, Sweden
    Not yet recruiting
  • Alingsås lasarett, department of general surgery, urology and orthopaedic surgery
    Alingsås, Sweden
    Recruiting
  • NU sjukvården, Uddevalla sjukhus, department of urology
    Uddevalla, Sweden
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jan 2027, 22 months after the start.

Of 59 non-industry observational studies under Prostatic Hyperplasia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 22 months is below that.

Counting every sponsor, half of 74 studies reached it within 25 months; a quarter within 12 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2025
First posted
Feb 28, 2025
StartActual
Mar 15, 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jan 31, 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Kungälvs sjukhus, department of urology · Kungälv, Sweden
Show 1 removed
  • Kungälvs sjukhus, department of urology · Kungälv, Sweden
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    1 site added, 1 site removed
    Show site
    • Kungälvs sjukhus, department of urology · Kungälv, Sweden
    Show 1 removed
    • Kungälvs sjukhus, department of urology · Kungälv, Sweden
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06852859
Responsible party
Joakim Stromberg (Associate professor, Sahlgrenska University Hospital) — Principal investigator
First posted
Feb 28, 2025
Start date
Mar 15, 2025
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Joakim BE Strömberg, MD, PhD
Contact
joakim.stromberg@vgregion.se
46-768-341-327
Joakim BE Strömberg, MD, PhD
principal investigator · Sahlgrenska University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion